FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2770618238> ?p ?o ?g. }

• W2770618238 endingPage "70" @default.
• W2770618238 startingPage "57" @default.
• W2770618238 abstract "The majority of patients with CLL will suffer from infections during their disease, accounting for approximately 60% of deaths in CLL. Patients are predisposed to infection due to immune defects related to the primary disease, and as a result of therapy. The range of infectious complications has evolved alongside therapeutic advances in the treatment of CLL. More recently several novel therapeutic compounds have been introduced in CLL, whose unique safety profiles will probably have an impact on the prophylaxis and management of infections in these patients. Areas covered: This review describes the pathogenesis of infections due to intrinsic CLL or therapy-related immunosuppression, and elightens the importance of proactive and reactive infection management as a key focus of patient care. Infections related to conventional chemotherapy, immunochemotherapy with monoclonal antibodies, target therapies with B-cell receptor pathway inhibitors and Bcl-2 antagonists are reviewed. Expert commentary: Despite the importance of infection management and prevention in high-risk patients, there are only limited infection risk-assessment guidelines that can be easily used in clinical practice to guide more appropriate infection prophylaxis and its management. Here we provide an overview of suggested prophylaxis management of infection, and include key prophylactic interventions that we feel should be performed in CLL patients routinely." @default.
• W2770618238 created "2017-12-04" @default.
• W2770618238 creator A5025358969 @default.
• W2770618238 creator A5057017325 @default.
• W2770618238 creator A5062182046 @default.
• W2770618238 date "2017-11-27" @default.
• W2770618238 modified "2023-10-11" @default.
• W2770618238 title "A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia" @default.
• W2770618238 cites W1512989847 @default.
• W2770618238 cites W1513269339 @default.
• W2770618238 cites W1525326448 @default.
• W2770618238 cites W1531474084 @default.
• W2770618238 cites W1557367249 @default.
• W2770618238 cites W1690008797 @default.
• W2770618238 cites W1966676810 @default.
• W2770618238 cites W1969252807 @default.
• W2770618238 cites W1971440631 @default.
• W2770618238 cites W1975646531 @default.
• W2770618238 cites W1978296779 @default.
• W2770618238 cites W1979590202 @default.
• W2770618238 cites W1980884743 @default.
• W2770618238 cites W1982079252 @default.
• W2770618238 cites W1984134914 @default.
• W2770618238 cites W1984412456 @default.
• W2770618238 cites W1986535649 @default.
• W2770618238 cites W1986924929 @default.
• W2770618238 cites W1992071011 @default.
• W2770618238 cites W1994630947 @default.
• W2770618238 cites W2002201421 @default.
• W2770618238 cites W2002216123 @default.
• W2770618238 cites W2006294701 @default.
• W2770618238 cites W2007836097 @default.
• W2770618238 cites W2010872995 @default.
• W2770618238 cites W2011474745 @default.
• W2770618238 cites W2012234169 @default.
• W2770618238 cites W2012630504 @default.
• W2770618238 cites W2013176883 @default.
• W2770618238 cites W2013330239 @default.
• W2770618238 cites W2015120596 @default.
• W2770618238 cites W2015165010 @default.
• W2770618238 cites W2016302707 @default.
• W2770618238 cites W2017202925 @default.
• W2770618238 cites W2018847258 @default.
• W2770618238 cites W2022163339 @default.
• W2770618238 cites W2027092131 @default.
• W2770618238 cites W2031317669 @default.
• W2770618238 cites W2032425389 @default.
• W2770618238 cites W2033274595 @default.
• W2770618238 cites W2036586160 @default.
• W2770618238 cites W2036746240 @default.
• W2770618238 cites W2037299101 @default.
• W2770618238 cites W2037388547 @default.
• W2770618238 cites W2037525909 @default.
• W2770618238 cites W2038592860 @default.
• W2770618238 cites W2039893797 @default.
• W2770618238 cites W2046926217 @default.
• W2770618238 cites W2049552447 @default.
• W2770618238 cites W2049740914 @default.
• W2770618238 cites W2053683902 @default.
• W2770618238 cites W2058786179 @default.
• W2770618238 cites W2060018629 @default.
• W2770618238 cites W2065084603 @default.
• W2770618238 cites W2066564017 @default.
• W2770618238 cites W2066976900 @default.
• W2770618238 cites W2067994772 @default.
• W2770618238 cites W2070487917 @default.
• W2770618238 cites W2079218247 @default.
• W2770618238 cites W2084366804 @default.
• W2770618238 cites W2088228079 @default.
• W2770618238 cites W2088373095 @default.
• W2770618238 cites W2088619423 @default.
• W2770618238 cites W2089103836 @default.
• W2770618238 cites W2089344948 @default.
• W2770618238 cites W2095447519 @default.
• W2770618238 cites W2095796858 @default.
• W2770618238 cites W2096373158 @default.
• W2770618238 cites W2108206643 @default.
• W2770618238 cites W2108374688 @default.
• W2770618238 cites W2110134415 @default.
• W2770618238 cites W2114733074 @default.
• W2770618238 cites W2116022383 @default.
• W2770618238 cites W2119612035 @default.
• W2770618238 cites W2120319857 @default.
• W2770618238 cites W2123049617 @default.
• W2770618238 cites W2127352239 @default.
• W2770618238 cites W2128631476 @default.
• W2770618238 cites W2129479803 @default.
• W2770618238 cites W2131078883 @default.
• W2770618238 cites W2131621311 @default.
• W2770618238 cites W2132117495 @default.
• W2770618238 cites W2133877408 @default.
• W2770618238 cites W2134110801 @default.
• W2770618238 cites W2134524335 @default.
• W2770618238 cites W2140606816 @default.
• W2770618238 cites W2142099365 @default.
• W2770618238 cites W2142604819 @default.
• W2770618238 cites W2142983050 @default.
• W2770618238 cites W2143749371 @default.

• next